News

Every investor has different timelines and goals, and the stocks they select to fill a portfolio should mirror those goals. While some may not care about dividends, others value them highly, even if

Fool.com contributor Parkev Tatevosian reviews AT&T's (NYSE: T) long-term debt regarding its ability to pay dividends.

*Stock prices used were the afternoon prices of Aug. 19, 2023. The video was

Fool.com contributor Parkev Tatevosian provides insights into AT&T's (NYSE: T) near-term prospects.

*Stock prices used were the afternoon prices of Aug. 18, 2023. The video was published on Aug

Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to

A new bull market is here ... almost. Some maintain that the S&P 500 has already begun a new bull market. Others, though, argue that the index must reach an all-time high first. Either way, many

Investors have enjoyed some generous returns so far in 2023, with the S&P 500 up 17% and the tech-heavy Nasdaq up 31% as of this writing. Given these returns, investor expectations have been

Over the past few years, several hot investing trends swept through Wall Street. First, it was the metaverse, and now it's artificial intelligence; there will likely be some new big thing in a year

Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.

Fool.com contributor Parkev Tatevosian compares AT&T (NYSE: T) and Altria (NYSE: MO) across critical financial metrics, including the dividend yield, to determine which is the best stock to buy for

Don't let anyone tell you that you must have a boatload of money to get started investing in stocks. It's simply not true. Sure, you'll need some upfront cash. However, even a modest amount is

AT&T (NYSE: T) has continued on a downward slide. Massive debt levels and the end of a 35-year streak of dividend increases rattled investors, and its dividend yield of 7.7% failed to stem the

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Shares in medical technology company Koninklijke Philips (NYSE: PHG), also called Royal Philips, rose by 9.5% in the week through Friday morning. The move comes as Philips unveiled a relationship

Over the past few years, medical device companies have struggled as the pandemic disrupted much of the industry, and economic problems contributed to lower sales and increasing expenses. Healthcare

Blindly buying dividend stocks with sky-high yields can be a recipe for disaster. A high dividend yield often comes with an elevated risk that the dividend isn't sustainable.

AT&T (NYSE: T) and

Novavax (NASDAQ: NVAX) has gone from a pandemic darling to a bust, with its shares falling by a whopping 83% over the past 12 months. The hope and optimism surrounding the stock has faded. Earlier

UnitedHealth Group (NYSE: UNH) has been a top healthcare stock to own for years. Today, it's among the largest healthcare companies in the world, worth $475 billion. Although it's a health insurer

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Pharma giant AbbVie (NYSE: ABBV) performed poorly in the first part of the year, especially after it reported its first-quarter results. This was its first quarterly update following the loss of

Illumina's (NASDAQ: ILMN) stock is down by 15% this year so far, and it's no surprise why. With the new disclosure of a Securities and Exchange Commission (SEC) investigation into its bedraggled